comparemela.com

Latest Breaking News On - Prnewswire axsome therapeutics inc - Page 1 : comparemela.com

Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry

/PRNewswire/ Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central.

New yorkUnited statesHerriot tabuteauMark jacobsonPrnewswire axsome therapeutics incAxsome therapeutics incDrug administrationHarvard medical schoolDepartment of psychiatryDean for clinical translational researchClinical trials network instituteMajor depressive disorderClinical trialClinical psychiatryMaurizio favaMassachusetts general hospital

Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry

/PRNewswire/ Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central.

New yorkUnited statesNew york universityHerriot tabuteauMark jacobsonDan iosifescuNathan kline institute for psychiatric researchPrnewswire axsome therapeutics incAxsome therapeutics incYork university school of medicineClinical research divisionMajor depressive disorderControlled trialAmerican journalNew york university schoolNathan kline institute

Axsome Therapeutics Completes U S Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Axsome is committed to providing patients uninterrupted access to Sunosi and advancing research for patients living with sleep disorders Insurance coverage for.

New yorkUnited statesHerriot tabuteauRichardk boganAndrew krystalMark jacobsonSk biopharmaceuticals co ltdPrnewswire axsome therapeutics incAxsome therapeutics incJazz pharmaceuticalsDrug administrationContinuous positive airway pressureDepartment of psychiatryEuropean medicines agencyUs drug enforcement agency onAirway pressure

Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Company to host conference call today at 8:00 AM EasternNEW YORK, May 2, 2022 /PRNewswire/ Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharm.

New yorkUnited statesHerriot tabuteauMark jacobsonPrnewswire axsome therapeutics incAxsome therapeutics incJazz pharmaceuticalsDrug administrationChief executive officerBreakthrough therapyNew drug applicationPriority reviewDisease agitationComplete response letterAntitrust improvements actDigital centric commercialization

Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine

Press release content from PR Newswire. The AP news staff was not involved in its creation.

New yorkUnited statesHerriot tabuteauAxsome moMark jacobsonCenters for diseaseAmerican migraine foundationPrnewswire axsome therapeutics incAxsome therapeutics incDrug administrationComplete response letterNew drug applicationChief executive officerDisease controlAmerican migraineMolecular solubility enhanced inclusion complex

vimarsana © 2020. All Rights Reserved.